Abstract 4337
Background
The aim of this study is to report clinical features and treatment outcome of pineal parenchymal tumors (PPTs).
Methods
Between 2006-2017, medical records of 34 patients of PPTs were analyzed to study patterns of care of patients who received adjuvant radiotherapy (RT) with or without chemotherapy (CT) following surgery. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan- Meier method.
Results
According to WHO classification, the study comprises of 19 pineoblastomas (PB), 11 pineal parenchymal tumors of intermediate differentiation (PPTID) and 4 pineocytomas (PC). Median age at presentation was 10, 26 and 30 years, respectively. Headache was commonest symptom (77%) followed by visual disturbance. 59% underwent surgical resection and 41% had biopsy only. Median MIB labelling index of PPTIDs was 6%, whereas it was 35% in PB and 2% in PC. Spinal drop metastasis was present in 8 patients with PB and 3 patients with PPTIDs. All PBs and PPTIDs with spinal drop metastasis (2) received cranio-spinal irradiation (CSI) and adjuvant CT. The rest of the PPTIDs and PC received focal RT to the brain. The commonest regimen was a combination of carboplatin and etoposide (CE), used in 6 (32 %) PB. CE with vincristine and IT-MTX was given in patients who developed drop metastasis subsequently. At a median follow-up of 16 months, 9 (47%) patients of PB and 3 (27%) of PPTID developed recurrence in cranio-spinal axis. 5 year progression-free survival was 41%, 62% and 75%, respectively. Median overall survival (OS) was 27, 50, 18 months, and 5 year OS was 38%, 47% and 75%, respectively.
Conclusions
PPTs reflect a broad spectrum of malignant potential and prognosis. PB is an aggressive tumor and requires adjuvant CSI and CT following surgery. PPTIDs are relatively rare and require meticulous pretreatment evaluation of neuraxis and knowledge of pathological factors for management. Multi-institutional cooperation in the form of prospective studies is recommended in view of rarity of tumor.
Clinical trial identification
Legal entity responsible for the study
AIIMS, New Delhi.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract